La Jolla Pharmaceutical Company (LJPC) 2011年年度报告「NASDAQ」.pdf

1、Table of Contents UNITED STATESSECURITIES AND EXCHANGE COMMISSIONWASHINGTON,DC 20549 FORM 10-K xANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d)OF THE SECURITIES EXCHANGE ACT OF 1934For the fiscal year ended DECEMBER 31,2011OR TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d)OF THE SECURITIES EXCHANGE

2、ACT OF1934For the transition period from to Commission file number:0-24274 LA JOLLA PHARMACEUTICAL COMPANY(Exact name of registrant as specified in its charter)Delaware 33-0361285(State or other jurisdictionof incorporation or organization)(I.R.S.EmployerIdentification Number)4370 La Jolla Village D

3、rive,Suite 400,San Diego,CA 92122(Address of principal executive offices,including Zip Code)Registrants telephone number,including area code:(858)452-6600Securities registered pursuant to Section 12(b)of the Act:NoneSecurities registered pursuant to Section 12(g)of the Act:Common Stock,Par Value$0.0

4、001 per share Indicate by check mark if the registrant is a well-known seasoned issuer,as defined in Rule 405 of the Securities Act.Yes No xIndicate by check mark if the registrant is not required to file reports pursuant to Section 13 or 15(d)of the Act.Yes No xIndicate by check mark whether the re

5、gistrant:(1)has filed all reports required to be filed by Section 13 or 15(d)of the Securities Exchange Act of1934 during the preceding 12 months(or for such shorter period that the registrant was required to file such reports),and(2)has been subject to such filingrequirements for the past 90 days.Y

6、es x No Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site,if any,every Interactive Data Filerequired to be submitted and posted pursuant to Rule 405 of Regulation S-T during the preceding 12 months(or for such shorter period that the regi